[HTML][HTML] Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results
…, L Marshall, L Chesler, M Granger, AV Desai… - Nature medicine, 2023 - nature.com
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.
…, M Shinnar, DM Shindler, JE Wilson, A Desai… - The Journal of …, 2008 - jrheum.org
OBJECTIVE: Pulmonary hypertension (PH) is an ominous complication in patients with
scleroderma (systemic sclerosis, SSc). We compared noninvasive assessment of PH with …
scleroderma (systemic sclerosis, SSc). We compared noninvasive assessment of PH with …
[HTML][HTML] Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients
P Schuetz, P Maurer, V Punjabi, A Desai, DN Amin… - Critical Care, 2013 - Springer
Introduction Close monitoring and repeated risk assessment of sepsis patients in the intensive
care unit (ICU) is important for decisions regarding care intensification or early discharge …
care unit (ICU) is important for decisions regarding care intensification or early discharge …
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
AV Desai, GW Robinson, K Gauvain, EM Basu… - Neuro …, 2022 - academic.oup.com
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for
the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors …
the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors …
[HTML][HTML] The evolution of risk classification for neuroblastoma
E Sokol, AV Desai - Children, 2019 - mdpi.com
Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are
risk-stratified using a number of features including age at diagnosis, disease stage, tumor …
risk-stratified using a number of features including age at diagnosis, disease stage, tumor …
[HTML][HTML] A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
Background Improved usage of the repertoires of pancreatic ductal adenocarcinoma (PDAC)
profiles is crucially needed to guide the development of predictive and prognostic tools that …
profiles is crucially needed to guide the development of predictive and prognostic tools that …
[PDF][PDF] Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion
…, L Alba-Castellón, P Baskaran, I Quétier, A Desai… - Cell Reports, 2022 - cell.com
In pancreatic ductal adenocarcinoma (PDAC), differentiation of pancreatic stellate cells (PSCs)
into myofibroblast-like cancer-associated fibroblasts (CAFs) can both promote and …
into myofibroblast-like cancer-associated fibroblasts (CAFs) can both promote and …
Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis
…, JC Luckett, AL Tatler, RO Awais, A Desai… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Transforming growth factor β activation by the αvβ6 integrin is central to the pathogenesis of
idiopathic pulmonary fibrosis. Expression of the αvβ6 integrin is increased in fibrotic lung …
idiopathic pulmonary fibrosis. Expression of the αvβ6 integrin is increased in fibrotic lung …
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
…, S Haider, A Brentnall, A Desai… - The Journal of …, 2019 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) has a 5‐year survival rate of less than 4% and
desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor …
desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor …
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors …
…, G Bergthold, E Chow Maneval, E Fox, AV Desai - 2019 - ascopubs.org
10009 Background: Entrectinib is a CNS-penetrant oral inhibitor of TrkA/B/C, ROS1 and
ALK tyrosine kinases. We report the efficacy of entrectinib in children with recurrent/refractory …
ALK tyrosine kinases. We report the efficacy of entrectinib in children with recurrent/refractory …